Patent application number | Description | Published |
20090012103 | SUBSTITUTED HETEROCYCLIC COMPOUNDS - The present invention relates to novel heterocyclic compounds and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula (I): | 01-08-2009 |
20090099212 | A3 ADENOSINE RECEPTOR ANTAGONISTS - Disclosed are novel methods of antagonizing the A | 04-16-2009 |
20090105283 | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS - The present invention discloses 3-hydroquinazolin-4-one derivatives for use as inhibitors of stearoyl-CoA desaturase. The compounds are useful in treating and/or preventing various human diseases, mediated by stearoyl-CoA desaturase (SCD) enzymes, especially diseases related to abnormal lipid levels, cancer, cardiovascular disease, diabetes, obesity, metabolic syndrome and the like. | 04-23-2009 |
20090137520 | A1 ADENOSINE RECEPTOR AGONISTS - Disclosed are novel compounds that are A | 05-28-2009 |
20090137802 | A2B ADENOSINE RECEPTOR ANTAGONISTS - Disclosed are processes for the synthesis of novel compounds that are A | 05-28-2009 |
20090209533 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION - Disclosed are novel isoflavone derivatives having the structure of Formula I | 08-20-2009 |
20090247557 | PARTIAL AND FULL AGONISTS OF A1 ADENOSINE RECEPTORS - Disclosed are novel compounds a compound of Formula I | 10-01-2009 |
20090253693 | 2H-BENZO[b][1,4]OXAZIN-3(4H)-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS - The present invention discloses 2H-benzo[b][1,4]oxazin-3(4H)-one derivatives for use as inhibitors of stearoyl-CoA desaturase having the structure of Formula I: | 10-08-2009 |
20090253704 | PYRROLOTRIAZINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS - The present invention discloses pyrrolotriazinone derivatives for use as inhibitors of stearoyl-CoA desaturase having the structure of Formula I: | 10-08-2009 |
20090253738 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS - The present invention discloses triazolopyridinone derivatives for use as inhibitors of stearoyl-CoA desaturase having the structure of Formula I: | 10-08-2009 |
20090325896 | PARTIAL AND FULL AGONISTS OF A1 ADENOSINE RECEPTORS - Disclosed are novel compounds that are partial and full A | 12-31-2009 |
20100056538 | Pro-drugs of A2B Adenosine Receptor Antagonists - Disclosed are prodrugs of A | 03-04-2010 |
20100113449 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS - The present invention relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula (IA) or (IB): | 05-06-2010 |
20100113461 | SUBSTITUTED HETEROCYCLIC COMPOUNDS - The present invention relates to compounds that are late sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula (I): | 05-06-2010 |
20100113463 | PTERIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS - The present invention discloses pteridinone derivatives for use as inhibitors of stearoyl-CoA desaturase having the structure of Formula I: | 05-06-2010 |
20100113514 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS - The present invention relates to sodium channel inhibitors of Formula : | 05-06-2010 |
20100125091 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS - The present invention relates to sodium channel inhibitors of Formula (I): | 05-20-2010 |
20100197684 | SUBSTITUTED HETEROCYCLIC COMPOUNDS - The present invention relates to novel heterocyclic compounds and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula (I): | 08-05-2010 |
20100204238 | BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS FOR USE AS STEAROYL CoA DESATURASE INHIBITORS - The present invention discloses bicyclic nitrogen-containing heterocyclic compounds for use as inhibitors of stearoyl-CoA desaturase. The compounds are useful in treating and/or preventing various human diseases, mediated by stearoyl-CoA desaturase (SCD) enzymes, especially diseases related to abnormal lipid levels, cardiovascular disease, diabetes, obesity, oily skin conditions, metabolic syndrome, and the like. | 08-12-2010 |
20100210579 | PARTIAL AND FULL AGONISTS OF A1 ADENOSINE RECEPTORS - Disclosed are novel compounds a compound of Formula I | 08-19-2010 |
20100222300 | A2B Adenosine Receptor Antagonists - Disclosed are novel compounds that are A | 09-02-2010 |
20100267748 | HETEROCYCLIC COMPOUNDS USEFUL AS STEAROYL CoA DESATURASE INHIBITORS - The present invention discloses 1H-pyrido[1,2-a]pyrimidin-4(9aH)-one derivatives or 1H-pyrimido[1,2-a]pyrimidin-4(9aH)-one derivatives for use as inhibitors of stearoyl-CoA desaturase having the structure of Formula I: | 10-21-2010 |
20100267752 | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS - The present invention discloses 3-hydroquinazolin-4-one derivatives for use as inhibitors of stearoyl-CoA desaturase. The compounds are useful in treating and/or preventing various human diseases, mediated by stearoyl-CoA desaturase (SCD) enzymes, especially diseases related to abnormal lipid levels, cancer, cardiovascular disease, diabetes, obesity, metabolic syndrome and the like. | 10-21-2010 |
20110021521 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS - The present invention relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: | 01-27-2011 |
20110130362 | A2B ADENOSINE RECEPTOR ANTAGONISTS - Disclosed are novel compounds that are A | 06-02-2011 |
20110257127 | A2B ADENOSINE RECEPTOR ANTAGONISTS - Disclosed are novel compounds that are A | 10-20-2011 |
20120004267 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS - The present invention relates to compounds of Formula (I): | 01-05-2012 |
20120010192 | Fused Heterocyclic Compounds as Ion Channel Modulators - The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: | 01-12-2012 |
20120065227 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS - The present invention discloses triazolopyridinone derivatives for use as inhibitors of stearoyl-CoA desaturase having the structure of Formula I: | 03-15-2012 |
20120289493 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS - The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: | 11-15-2012 |
20130005689 | COMPOUNDS FOR THE TREATMENT OF ADDICTION - Disclosed are novel compounds having the structure of Formula (I): | 01-03-2013 |
20130005706 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS - The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: | 01-03-2013 |
20130012492 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS - The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: | 01-10-2013 |
20130096122 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS - The present invention relates to sodium channel inhibitors of Formula I: | 04-18-2013 |
20130102632 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS - The present invention relates to sodium channel inhibitors of Formula (I): | 04-25-2013 |
20130123280 | A2B ADENOSINE RECEPTOR ANTAGONISTS - Disclosed are novel compounds that are A | 05-16-2013 |
20130184255 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS - The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: | 07-18-2013 |
20130197001 | SUBSTITUTED HETEROCYCLIC COMPOUNDS - The present invention relates to compounds that are late sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula (I): | 08-01-2013 |
20130203704 | COMPOUNDS FOR THE TREATMENT OF ADDICTION - Disclosed are novel compounds having the structure of Formula (I): | 08-08-2013 |
20130203819 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS - The present invention relates to compounds of Formula (I): | 08-08-2013 |
20130231325 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION - Disclosed are novel isoflavone derivatives having the structure of Formula I: | 09-05-2013 |
20130324525 | SUBSTITUTED HETEROCYCLIC COMPOUNDS - The present invention relates to novel heterocyclic compounds and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula (I): | 12-05-2013 |
20140017198 | INHIBITORS OF HEPATITIS C VIRUS - Compounds of Formula I are disclosed | 01-16-2014 |
20140051668 | COMPOUNDS FOR THE TREATMENT OF ADDICTION - Disclosed are novel compounds having the structure of Formula (I): | 02-20-2014 |
20140094460 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS - The present invention relates to sodium channel inhibitors of Formula I: | 04-03-2014 |
20140107155 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS - The present invention relates to sodium channel inhibitors of Formula (I): | 04-17-2014 |
20140135317 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS - The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: | 05-15-2014 |
20140274884 | INHIBITORS OF HEPATITIS C VIRUS - Compounds of formula I: | 09-18-2014 |
20140296246 | BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS - This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, a bromodomain-containing protein, including bromodomain-containing protein 4 (BRD4), and to compositions and formulations containing such compounds, and methods of using and making such compounds. Compounds include compounds of Formula (I) | 10-02-2014 |
20140303158 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS - The present invention relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: | 10-09-2014 |
20140336190 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS - This application relates to chemical compounds which may act as inhibitors of; or which may otherwise modulate the activity of, a bromodomain-containing protein, including bromodomain-containing protein 4 (BRD4), and to compositions and formulations containing such compounds, and methods of using and making such compounds. Compounds include compounds of Formula (I) | 11-13-2014 |
20150038488 | SYK INHIBITORS - The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I | 02-05-2015 |
20150080370 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS - The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: | 03-19-2015 |